Both in Biotechnology
Coherus Oncology vs Humacyte
Over the past year CHRS returned −46.4% and HUMA returned −71.9%; their daily moves had a correlation of 0.19.
CHRS −46.4% HUMA −71.9%Growth of $1, one year, split-adjusted
| Metric | CHRS | HUMA |
|---|---|---|
| Price | $0.8573 | $0.4465 |
| Market cap | $132.5M | $124.0M |
| Today | +6.42% | +1.36% |
| 1 month | −16.8% | −6.6% |
| 6 months | −51.0% | −54.6% |
| Year to date | −39.6% | −53.5% |
| 1 year | −46.4% | −71.9% |
| Revenue growth (YoY) | +39.5% | +34.9% |
| Gross margin | 70.4% | −203.2% |
| Net margin | −144.2% | −9064.5% |
| P/E (TTM) | — | — |
| Price / sales | 2.6× | 58.5× |
| Net cash | $68.1M | $13.7M |
| Dividend yield | — | — |
| Volatility (60d) | 95.6% | 107.8% |
| Short % of float | 9.5% | 11.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).